LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Kodu・Aktsiate loetelu・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Suletud

SektorTervishoid

2.56 -9.22

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.56

Max

2.61

Põhinäitajad
By Trading Economics
Sissetulek	4.1M -5.7M
Töötajad	34
EBITDA	3.1M -6.8M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+678.21% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	9. juuni 2026

Turustatistika
By TradingEconomics
Turukapital	-113M 276M
Eelmine avamishind	11.78
Eelmine sulgemishind	2.56

Uudiste sentiment

By Acuity

50%

139 / 344 Pingereas Healthcare

Anavex Life Sciences Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. juuni 2026, 19:20 UTC

Suurimad hinnamuutused turgudel

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7. juuni 2026, 23:46 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7. juuni 2026, 23:36 UTC

Market Talk

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7. juuni 2026, 18:00 UTC

Tulu

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6. juuni 2026, 12:40 UTC

Omandamised, ülevõtmised, äriostud

Correction to Texas Billionaires Article America's Resort -- WSJ

6. juuni 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6. juuni 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. juuni 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. juuni 2026, 00:14 UTC

Omandamised, ülevõtmised, äriostud

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5. juuni 2026, 21:27 UTC

Tulu

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5. juuni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. juuni 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5. juuni 2026, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5. juuni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. juuni 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. juuni 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5. juuni 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5. juuni 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5. juuni 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5. juuni 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5. juuni 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5. juuni 2026, 18:33 UTC

Omandamised, ülevõtmised, äriostud

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5. juuni 2026, 17:50 UTC

Tulu

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5. juuni 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5. juuni 2026, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. juuni 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5. juuni 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5. juuni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Anavex Life Sciences Corp Prognoos

Hinnasiht

By TipRanks

678.21% tõus

12 kuu keskmine prognoos

Keskmine 20 USD 678.21%

Kõrge 20 USD

Madal 20 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Anavex Life Sciences Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Anavex Life Sciences Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

139 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.